Market Closed -
Nasdaq Stockholm
11:18:41 2024-04-29 am EDT
|
5-day change
|
1st Jan Change
|
0.25
SEK
|
+6.38%
|
|
+6.38%
|
-50.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
388.2
|
355.9
|
248.8
|
21.33
|
Enterprise Value (EV)
1 |
361.1
|
291.6
|
197.5
|
12.4
|
P/E ratio
|
-24.1
x
|
-20.4
x
|
-11.1
x
|
-0.52
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
521
x
|
571
x
|
16
x
|
73
x
|
EV / Revenue
|
485
x
|
468
x
|
12.7
x
|
42.5
x
|
EV / EBITDA
|
-26.2
x
|
-18
x
|
-9.28
x
|
-0.3
x
|
EV / FCF
|
65,515,346
x
|
-30,539,026
x
|
-31,696,511
x
|
-516,671
x
|
FCF Yield
|
0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
14.5
x
|
6.02
x
|
5.53
x
|
9.94
x
|
Nbr of stocks (in thousands)
|
23,584
|
26,384
|
29,977
|
28,977
|
Reference price
2 |
16.46
|
13.49
|
8.300
|
0.7360
|
Announcement Date
|
5/12/20
|
4/23/21
|
4/28/22
|
4/26/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.3296
|
0.243
|
0.745
|
0.623
|
15.6
|
0.292
|
EBITDA
1 |
-2.207
|
-7.599
|
-13.79
|
-16.22
|
-21.27
|
-41.2
|
EBIT
1 |
-2.627
|
-7.634
|
-13.81
|
-16.26
|
-21.38
|
-41.47
|
Operating Margin
|
-797.03%
|
-3,141.56%
|
-1,853.42%
|
-2,610.59%
|
-137.09%
|
-14,202.05%
|
Earnings before Tax (EBT)
1 |
-2.627
|
-7.637
|
-13.81
|
-16.2
|
-21.29
|
-41.38
|
Net income
1 |
-2.627
|
-7.637
|
-13.81
|
-16.2
|
-21.29
|
-41.38
|
Net margin
|
-797.04%
|
-3,142.8%
|
-1,853.29%
|
-2,600.96%
|
-136.49%
|
-14,170.89%
|
EPS
|
-
|
-0.5100
|
-0.6832
|
-0.6600
|
-0.7482
|
-1.428
|
Free Cash Flow
|
-
|
-15.13
|
5.511
|
-9.549
|
-6.231
|
-24
|
FCF margin
|
-
|
-6,225.57%
|
739.78%
|
-1,532.74%
|
-39.94%
|
-8,219.09%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/30/18
|
5/29/19
|
5/12/20
|
4/23/21
|
4/28/22
|
4/26/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.56
|
1.17
|
27.1
|
64.3
|
51.3
|
8.93
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-15.1
|
5.51
|
-9.55
|
-6.23
|
-24
|
ROE (net income / shareholders' equity)
|
-75.6%
|
-85.2%
|
-66.9%
|
-35.8%
|
-39.7%
|
-181%
|
ROA (Net income/ Total Assets)
|
-33.7%
|
-41.9%
|
-37.1%
|
-21.6%
|
-22.1%
|
-73.4%
|
Assets
1 |
7.794
|
18.22
|
37.18
|
75.06
|
96.3
|
56.39
|
Book Value Per Share
|
-
|
0.9600
|
1.140
|
2.240
|
1.500
|
0.0700
|
Cash Flow per Share
|
-
|
0.0800
|
1.150
|
2.260
|
1.770
|
0.3100
|
Capex
|
-
|
-
|
-
|
0.32
|
0.77
|
0.46
|
Capex / Sales
|
-
|
-
|
-
|
50.72%
|
4.96%
|
157.19%
|
Announcement Date
|
5/30/18
|
5/29/19
|
5/12/20
|
4/23/21
|
4/28/22
|
4/26/23
|
|
1st Jan change
|
Capi.
|
---|
| -50.40% | 621K | | +26.47% | 661B | | +26.74% | 566B | | -6.33% | 352B | | +19.35% | 332B | | +4.23% | 283B | | +13.43% | 231B | | +4.71% | 200B | | -9.53% | 195B | | -4.04% | 145B |
Other Pharmaceuticals
|